EMG
MCRB icon

Ellington Management Group’s Seres Therapeutics MCRB Stock Holding History

Ellington Management Group’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-720
Closed -$99K – 698
2019
Q1 		$99K Buy
+720
New +$87.8K 0.02% 534
2017
Q2 		– Sell
-530
Closed -$119K – 796
2017
Q1 		$119K Sell
530
-10
-2% -$2.03K ﹤0.01% 634
2016
Q4 		$107K Buy
+540
New +$118K 0.02% 499

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Ellington Management Group's MCRB Position: Q2 2019 in Review

Ellington Management Group sold out of Seres Therapeutics (MCRB) in Q2 2019, closing a stake of 720 shares — an estimated $99K sold.

Ellington Management Group first reported a position in MCRB in Q4 2016 and held it in 3 quarters. The position peaked at $119K in Q1 2017. 91 funds tracked by Wall St. Rank hold MCRB as of Q2 2019.

  • Ellington Management Group reported no remaining Seres Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Ellington Management Group sold 720 Seres Therapeutics shares in Q2 2019, an estimated $99K.
  • Ellington Management Group first reported a position in Seres Therapeutics in Q4 2016 and held it in 3 quarters.
  • Ellington Management Group's Seres Therapeutics position peaked at $119K in Q1 2017.
  • 91 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2019.

Based on Ellington Management Group's 13F filing for Q2 2019, filed 14 Aug 2019.